2021年甘肃省胆囊癌流行现状及2010—2021年变化趋势分析
Trends of Incidence and Mortality of Gallbladder Cancer in Gansu Province from 2010 to 2021 and Prediction by Age-Period-Cohort Model
投稿时间:2026-01-22  修订日期:2026-03-16
DOI:
中文关键词:  胆囊癌  发病趋势  预测  贝叶斯年龄-时期-队列模型  甘肃
英文关键词:Gallbladder cancer  Incidence trend  Prediction  Bayesian age-period-cohort model  Gansu Province
基金项目:甘肃省自然科学基金(23JRRA1800);甘肃中医药大学公共卫生学院创新创业基金(2025.09-2026.09)
作者单位邮编
唐溪晗 甘肃中医药大学 730000
侯永钰 甘肃中医药大学 730000
曾雨欣 甘肃中医药大学 730000
刘玉琴 中山大学附属肿瘤医院甘肃医院 730000
丁高恒 中山大学附属肿瘤医院甘肃医院 730000
朱佳禾 悉尼大学 2006
田强霞 中山大学附属肿瘤医院甘肃医院 730050
王豆 中山大学附属肿瘤医院甘肃医院 730000
陈莉莉* 中山大学附属肿瘤医院甘肃医院 730050
摘要点击次数: 34
全文下载次数: 0
中文摘要:
      [目的]分析甘肃省2021年胆囊癌流行特征及2010—2021年发病率和死亡率趋势变化,并对2022—2030年发病流行情况进行预测,为制定针对性防控策略提供循证依据。[方法]基于甘肃省瘤登记处2010—2021年胆囊癌发病数据及人口学资料,按年龄、性别、城乡分层,计算粗发病率、死亡率与中国人口标化发病率(ASIRC)和中国人口标化死亡率(ASMRC),0~74岁累积发病率及世界人口标化发病/死亡率(简称世标率)等;采用 Joinpoint 回归模型分析趋势并计算年度变化百分比(Average Percentage Change,APC)和平均年度变化百分比(average annual percentage change,AAPC)及其95%置信区间(confidence interval,CI);应用贝叶斯年龄-时期-队列(BAPC)模型预测 2022—2030年发病率和死亡率。[结果]2021年,甘肃省胆囊癌ASIRC为3.02/10万,女性(3.19/10万)高于男性(2.85/10万);农村(3.06/10万)高于城市(2.93/10万)。 ASMRC为1.67/10万,女性(1.83/10万)高于男性(1.50/10万);城市(1.82/10万)高于农村(1.57/10万)。胆囊癌发病率和死亡率均随年龄增长而升高,在≥80岁年龄组达高峰(29.85/10万和25.66/10万)。2010—2021年间,全省胆囊癌粗发病率由3.64/10万升至4.99/10万(AAPC=4.51%),粗死亡率由1.98/10万升至2.92/10万(AAPC=1.85%),但经年龄标准化后,发病与死亡的变化趋势均无统计学意义。预测显示,2022—2030年甘肃省胆囊癌ASIRC将呈上升趋势,预计2030年达4.32/10万,较2021年上升43.04%;而ASMRC则呈下降趋势。[结论] 甘肃省胆囊癌疾病负担呈加重趋势,人口老龄化是主要驱动因素。农村地区、男性群体及高龄人群发病风险凸显。未来需采取精准化分层防控策略,强化农村地区健康干预、高危人群筛查及规范诊疗,以遏制疾病负担增长。
英文摘要:
      [Objective] To analyze the epidemic characteristics of gallbladder cancer in Gansu Province in 2021, examine the trends in incidence and mortality from 2010 to 2021, and predict the disease incidence from 2022 to 2030, thereby providing evidence for formulating targeted prevention and control strategies.[Methods] Based on gallbladder cancer incidence data and demographic information from the Gansu Provincial Cancer Registry (2010–2021), we stratified the data by age, sex, and urban/rural residence. We calculated the crude incidence and mortality rates, age-standardized incidence and mortality rates using the Chinese standard population (ASIRC and ASMRC), cumulative incidence (0–74 years), and world age-standardized rates. Trends were analyzed using the Joinpoint regression model to estimate the annual percentage change (APC) and average annual percentage change (AAPC) with corresponding 95% confidence intervals (CIs). A Bayesian age-period-cohort (BAPC) model was applied to predict incidence and mortality rates for 2022–2030.[Results]In 2021, the ASIRC for gallbladder cancer in Gansu Province was 3.02 per 100,000, with higher rates in females (3.19 per 100,000) than males (2.85 per 100,000), and in rural (3.06 per 100,000) than urban areas (2.93 per 100,000). The ASMRC was 1.67 per 100,000, with higher rates in females (1.83 per 100,000) than males (1.50 per 100,000), and in urban (1.82 per 100,000) than rural areas (1.57 per 100,000). Both incidence and mortality increased with age, peaking in the ≥80 age group (29.85 and 25.66 per 100,000, respectively). From 2010 to 2021, the crude incidence rate increased from 3.64 to 4.99 per 100,000 (AAPC = 4.51%), and the crude mortality rate increased from 1.98 to 2.92 per 100,000 (AAPC = 1.85%). However, after age standardization, the trends in incidence and mortality were not statistically significant. Predictions indicate that the ASIRC for gallbladder cancer in Gansu will show an upward trend from 2022 to 2030, reaching 4.32 per 100,000 by 2030, a 43.04% increase from 2021. In contrast, the ASMRC is projected to decline.[Conclusion] The disease burden of gallbladder cancer in Gansu Province is expected to intensify in the coming years, primarily driven by population aging. Elevated disease risks are notable in rural areas, among males, and in older age groups. Implementing precise, stratified prevention and control strategies is imperative. This includes strengthening health interventions in rural regions, enhancing screening in high-risk populations, and promoting standardized diagnosis and treatment to curb the growing disease burden.
在线阅读     查看/发表评论  下载PDF阅读器